دورية أكاديمية
أعرض في EDS

Application of the Central Nervous System International Prognostic Index (CNS-IPI) score in daily practice: a retrospective analysis apart from the clinical trial at two centers in Brazil.

التفاصيل البيبلوغرافية
العنوان: Application of the Central Nervous System International Prognostic Index (CNS-IPI) score in daily practice: a retrospective analysis apart from the clinical trial at two centers in Brazil.
المؤلفون: Fischer T; Santa Casa de Sao Paulo School of Medical Sciences, São Paulo SP, Brazil; Ac Camargo Cancer Center, São Paulo, SP, Brazil. Electronic address: thais.fischer@accamargo.org.br., Zing NP; Santa Casa de Sao Paulo School of Medical Sciences, São Paulo SP, Brazil., Fortier SC; Santa Casa de Sao Paulo School of Medical Sciences, São Paulo SP, Brazil., Schmidt J; Ac Camargo Cancer Center, São Paulo, SP, Brazil., Silveira TB; Santa Casa de Sao Paulo School of Medical Sciences, São Paulo SP, Brazil; Ac Camargo Cancer Center, São Paulo, SP, Brazil., Chiattone CS; Santa Casa de Sao Paulo School of Medical Sciences, São Paulo SP, Brazil.
المصدر: Hematology, transfusion and cell therapy [Hematol Transfus Cell Ther] 2024 Apr-Jun; Vol. 46 (2), pp. 137-145. Date of Electronic Publication: 2023 Mar 21.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Elsevier Editora Ltda Country of Publication: Brazil NLM ID: 101725732 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2531-1387 (Electronic) Linking ISSN: 25311379 NLM ISO Abbreviation: Hematol Transfus Cell Ther Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: [Rio de Janeiro, Brazil] : Elsevier Editora Ltda, [2018]-
مستخلص: Introduction: The diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma (NHL) and, despite all the progress in this field, central nervous system infiltration (CNSi) still occurs at an incidence of 2-10%. The objective of the present study was to evaluate the Central Nervous System International Prognostic Index (CNS-IPI) score in daily practice regarding the reproducibility in a heterogeneous cohort apart from a clinical trial.
Methods: Primary DLBCL patients were eligible for this study, between January 2007 and January 2017. All patients were treated with rituximab-based chemotherapy, mostly R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone). The CNSi was diagnosed by liquor (positive cytology and/or immunophenotype), computerized tomography, magnetic resonance image and/or fluorodeoxy-glucose-positron emission tomography, requested only in symptomatic patients when the CNSi was clinically suspected. The CNS-IPI was assessed by graphical comparison and calibration.
Results: After applying the inclusion/exclusion criteria, 322 patients were available for the analysis. The median follow-up was 60 months and the median age was 58 years. Seven patients experienced CNSi, characterizing an incidence of 2.17% (7/322). Comparing groups of patients with and without CNSi, we observed that the lactate dehydrogenase (LDH), number of extranodal sites, IPI, kidney/adrenal and absence of complete response were statistically different. The CNS-IPI model stratified patients in a three-risk group model as low-, intermediate- and high-risk. In our cohort, using the same stratification, we obtained an equivalent the 2-year rate of CNS relapse of 0.0%, 0.8% and 13.8%, respectively.
Conclusion: Our study reinforces the reproducibility of the CNS-IPI, specifically apart from clinical trials, and suggests the CNS-IPI score as a tool to guide therapy.
Competing Interests: Conflicts of interest The authors declare that they have no conflicts of interest.
(Copyright © 2023 Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular. Published by Elsevier España, S.L.U. All rights reserved.)
References: Blood. 2019 Feb 28;133(9):919-926. (PMID: 30617197)
Br J Haematol. 2012 Oct;159(1):39-49. (PMID: 22849793)
J Clin Oncol. 2016 Sep 10;34(26):3150-6. (PMID: 27382100)
Cancer Sci. 2018 Jan;109(1):225-230. (PMID: 29151258)
Leukemia. 2022 Sep;36(9):2151-2164. (PMID: 35701522)
Br J Haematol. 2017 Jan;176(2):210-221. (PMID: 27739058)
N Engl J Med. 2022 Jan 27;386(4):351-363. (PMID: 34904799)
J Clin Oncol. 2007 Feb 10;25(5):579-86. (PMID: 17242396)
Blood. 2016 May 19;127(20):2375-90. (PMID: 26980727)
Int J Hematol. 2009 Jun;89(5):577-83. (PMID: 19353238)
Leuk Lymphoma. 2014 Jun;55(6):1345-9. (PMID: 24004183)
Curr Oncol Rep. 2015 Jun;17(6):25. (PMID: 25912004)
N Engl J Med. 2018 Apr 12;378(15):1396-1407. (PMID: 29641966)
Blood. 2022 Apr 21;139(16):2499-2511. (PMID: 34995350)
AJNR Am J Neuroradiol. 2011 Jun-Jul;32(6):984-92. (PMID: 20616176)
J Clin Oncol. 2014 Sep 20;32(27):3059-68. (PMID: 25113753)
Br J Cancer. 2014 Sep 9;111(6):1072-9. (PMID: 25072255)
Cancer Sci. 2012 Feb;103(2):245-51. (PMID: 22044593)
Ann Oncol. 2010 May;21(5):1046-52. (PMID: 19861575)
Blood. 2016 May 5;127(18):2182-8. (PMID: 26834242)
Lancet Oncol. 2008 Feb;9(2):105-16. (PMID: 18226581)
Eur J Cancer. 2017 Apr;75:195-203. (PMID: 28237865)
Cancer Res. 1971 Nov;31(11):1860-1. (PMID: 5121694)
Br J Haematol. 2016 Dec;175(5):876-883. (PMID: 27681999)
Rev Bras Hematol Hemoter. 2013;35(4):256-62. (PMID: 24106443)
Ann Oncol. 2002 Jul;13(7):1099-107. (PMID: 12176790)
N Engl J Med. 1993 Sep 30;329(14):987-94. (PMID: 8141877)
J Clin Oncol. 2010 May 10;28(14):2373-80. (PMID: 20385988)
Br J Haematol. 2015 Mar;168(5):654-62. (PMID: 25312994)
فهرسة مساهمة: Keywords: Central nervous system; Intrathecal; Lymphoma; Methotrexate; Non-Hodgkin lymphoma; Rituximab
تواريخ الأحداث: Date Created: 20230421 Latest Revision: 20240607
رمز التحديث: 20240607
مُعرف محوري في PubMed: PMC11150491
DOI: 10.1016/j.htct.2023.02.003
PMID: 37085346
قاعدة البيانات: MEDLINE
الوصف
تدمد:2531-1387
DOI:10.1016/j.htct.2023.02.003